

Humber Area Prescribing Committee

Date / Time	7 th June 2023 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No – JM to send papers to (items ratified after meeting)

Attendance	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Luke Storr – Senior Pharmacy Technician, HUTH (LS) Joanne Goode – Chief Pharmacist – HUTH (JG) Prof M Lind-Professor of Oncology- HUTH (ML), Vice Chair HUTH D&TC – attending for Prof. A Morice Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS) Naida Rafiq- Medicines Optimisation Pharmacist- NECS (NR) Wayne Baxter- NECS (WB) Dr Rolan Schreiber, Professional Secretary LMC (RSc) Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Dr Anupam Sinha- NEL GP Prescribing Lead (AS) Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF) Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC) Gemma McNally-CHCP (GMc)
-------------------	--

Apologies	Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Narayana Pothina- Consultant in adult medicine, NLAG (NP) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Emma Baggaley, Assistant Director Medicines Management (Superintendent Pharmacist),CHCP (EB)
------------------	--

Agenda Number	Item	Discussion	Action	Lead	Due Date
2023.06.01	Apologies	Noted above			
2023.06.02	Declarations of interest	None			
2023.06.03	Minutes of previous meeting	Accepted as true record			
2023.06.04	Action Tracker	<p>Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies)</p> <p>Ratification of guidelines and SCFs Add type 2 diabetes guidelines as recommendation for discussion at IMOC (action complete) NEW actions To feedback IMOC recommendation to clinicians To feedback to APC when meeting between all services occurred December update – going around internal governances in trusts (HUTH/NLAG/Y&SFT/HDH) March update – still awaiting outcome from relevant governances, JM to discuss with Matthew Heppel May update-sent to RS, to review how to do costing</p> <p>Action tracker HERPC – Hydroxychloroquine SCF JM to prepare hydroxychloroquine SCF</p> <p>Outstanding actions from NLAPC Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs) December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole Feb update- Modafinil live in NEL Riluzole live in NEL</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p>	<p>AK/JM</p> <p>JM</p> <p>JM</p> <p>JM/RS</p>	<p>6/23</p> <p>8/23</p> <p>6/23</p> <p>6/23</p>

		<p>March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update May update: Riluzole updated, modafinil still waiting for NL,mycophenolate to review Outstanding actions from NLAPC Funding for SCF – Azathioprine/6MP (NEL/N) AK to provide RS information on number of patients in NEL/NL Feb update Azathioprine live in NEL March update: SCF uploaded onto website, awaiting NL – RS to update May update: AK to check netformulary and Humber APC site Outstanding actions from HERPC Renal repatriation: December update – JM to meet with renal Dec update – JM offered dates of meeting but no correspondence March update – Updating business case. May update- to meet with NHSE Ratification of joint formulary To upload chapter 13 on netformulary and remove HERPC chapter March update – still ongoing May update- still ongoing</p> <p>Traffic light status To update formulary and red list Ratification of guidelines and SCFs To add to website Ratification of joint formulary To add chapter 1 to netformulary (and remove HERPC chapter when complete) RTDC updates To update formulary with TAs which were approved Blueteq Non-compliance to NICE guidance in acute trusts and financial impact</p>	Action complete	AK	6/23
			Ongoing	JM	12/22
			Ongoing	JM/AK/LS	6/23
				AK/LS	6/23
				JM	6/23
				JM/LS/AK	9/23
				AK/JM	6/23
				JM	7/23
2023.06.05	Outstanding actions from HERPC	<ul style="list-style-type: none"> Correspondence Received Rheumatology to prepare pathway with rituximab without MTX August update – JM to contact Dr Ogumbambi for timeline 	Added to HUTH D&T agenda	JM	9/22

		<p>October update – JM to contact Dr Ogumbambi again November update – Arranging meeting to discuss guidance and timeframe December update – Meeting booked February update – Documents sent to Dr Ogumbambi – March update – JM chased Dr Ogumbambi as received NLAG documents April update – JM to chase Dr Ogumbambi again May update – To discuss at HUTH D&Tc and add to D&TC action tracker</p> <ul style="list-style-type: none"> Feedback From Commissioning Groups KMc and JM to work with CCG to approve MS guideline August update – JM to contact Gary Hepworth September update – JM updated document and to send to Gary Hepworth October update – JM sent to Gary Hepworth November update – Been circulated awaiting comments. December update – JM to update and send to guideline group for discussion February update – to add to next guideline group for discussion March update – to add to next guideline group Discussed at guideline group for next APC agenda April update – for next APC agenda May update – discussed on agenda Hydroxychloroquine SCF JM to discuss ophthalmology checks with rheumatology New action:JM to add Harrogate pathway to agenda when published. New Action: JM to meet with business manager in ophthalmology to discuss drafting HUTH pathway and work towards commissioning. September 2022 update – HUTH D&T are escalating internally via their escalation process. To prepare SCG (action for HAPC) October 2022 – HUTH D&TC haven't had reply from their escalation process (JM chasing) November 2022 – HUTH D&TC haven't had reply from their escalation process December 2022 – HUTH meeting later this month. February 2023 – To check PE&CE minutes March 2023 – To discuss PE&CE response at next D&TC April 2023 – To discuss at next HUTH D&TC May 2023 – re-escalated from HUTH D&TC 	<p>Ongoing- Add to next HAPC agenda</p> <p>Ongoing- JM to present to PE+CE</p>	<p>JM/KMc</p> <p>JM</p>	<p>4/23</p> <p>4/23</p>
--	--	--	--	-------------------------	-------------------------

		<ul style="list-style-type: none"> Prescribing guidelines – Dienogest pathway JM to confirm prescribing arrangements with specialist team October update: JM contacted Mrs Allen who is service lead, noted not stocked in HUTH pharmacy, thus stock arranged in pharmacy. No response from e-mail to consultant but specialist nurse responded. November update – JM to check formularies and EMIS dispensing system. December update – JM to chase consultant February update – JM met consultant and going to update pathway March update –JM to update pathway May update – JM not updated pathway yet 	Ongoing- add to next guideline agenda	JM	7/23
2023.06.06	Traffic Light Status	Hydrocortisone MR-RED Cefiderocol-RED Finerinone-AMBER 2 Eptinizumab-RED	Update formulary/red list	LS/AK	7/23
2023.06.07	Feedback from Integrated Medicines Optimisation Committee	Items discussed: Type 2 diabetes guidance NICE approval process Covid drugs Semeglutide Sub group feedback	Noted		
2023.06.08	Work plans	a) Joint formulary alignment b) Shared care frameworks c) Guidelines	Ongoing for information only		
2023.06.09	Ratification of guidelines and SCFs	a) Amber guidance-Orthostatic (Postural) hypotension EB had requested additional clarification around stockings and neurogenic hypotension. JM to update. b) Amber 2 guidance – Cenobamate New guidance due to issues with GP prescribing new antiepileptic. c) IBD Guidance – biologics and small molecules (HUTH only) New guidance from HUTH for IBD regarding management of patients on biologics and small molecules. This has been approved by relevant committees in HUTH (including D&TC) and contains the pathways of treatment of both ulcerative colitis and Crohns disease. Including switch of therapy and relevant NICE guidance. Generally is compliant with NICE guidance; the main difference is around use of infliximab	a) Update then Approved b) Approved c) Approved- HUTH only d) JM to update and present when updated	JM	7/23

		<p>in acute severe ulcerative colitis. The use of infliximab is the next IBD biologic audit that HUTH will complete. The ustekinumab audit report will be added to APC agenda when written up.</p> <p>d) Infliximab in acute severe ulcerative colitis (ASUC) This had be prepared as infliximab is the preferred agent for use for rescue therapy in ASUC both with HUTH and NLAG. NICE guidance recommends IV ciclosporin as first line agent and infliximab if this is not suitable. Further work required on paper including price per day day, price for ciclosporin levels, further details on dosing used with NLAG to be added.</p>			
2023.06.10	Ratification of joint formulary	Nil this month	Accepted		
2023.06.11	RTDC updates	<ul style="list-style-type: none"> April 23- to update formulary 	Update formulary/red list	JM/LS/AK	7/23
2023.06.13	Minutes from subcommittees	<p>a) Joint formulary subcommittee (Nil)</p> <p>b) Guideline subcommittee (March 2023)</p>	Attached for info only		
2023.06.14	Additional minutes for information	<p>a) HUTH D&TC (April 23)</p> <p>b) HFT DTG (Nil)</p> <p>c) NLAG M&T (Nil)</p> <p>d) NYY APC (May 23)</p>	Attached for info only		
2023.06.15	Correspondence received	Children's Ondansertron- discussions around the process and agreed that it should remain as RED.	JM to feedback to Paulash Haider.	JM	7/23
2023.06.16	AOB				
2023.06.17	Date of next meeting	5 th July 13.00 – 15.00 Teams			